Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.
You may also be interested in...
Sedative Hypnotic Class Labeling Warns Of Sleep-Driving And “Complex” Behaviors
FDA requests manufacturers of 13 sleep aids, including Ambien, Lunesta and Rozerem, to update labeling to advise of adverse events.
Sedative Hypnotic Class Labeling Warns Of Sleep-Driving And “Complex” Behaviors
FDA requests manufacturers of 13 sleep aids, including Ambien, Lunesta and Rozerem, to update labeling to advise of adverse events.
Sanofi-Aventis Rebates Aim To Accelerate Switch To Ambien CR
Firm is offering concessions to U.S. healthcare providers to switch patients to the extended-release formulation.